Applied Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.59
- Today's High:
- $1.79
- Open Price:
- $1.79
- 52W Low:
- $0.5
- 52W High:
- $2.73
- Prev. Close:
- $1.7
- Volume:
- 418361
Company Statistics
- Market Cap.:
- $47.58 million
- Book Value:
- 0.2
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -64.98%
- Return on Equity TTM:
- -197.73%
Company Profile
Applied Therapeutics Inc had its IPO on 2019-05-14 under the ticker symbol APLT.
The company operates in the Healthcare sector and Biotechnology industry. Applied Therapeutics Inc has a staff strength of 26 employees.
Stock update
Shares of Applied Therapeutics Inc opened at $1.79 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.59 - $1.79, and closed at $1.6.
This is a -5.88% slip from the previous day's closing price.
A total volume of 418,361 shares were traded at the close of the day’s session.
In the last one week, shares of Applied Therapeutics Inc have increased by +22.14%.
Applied Therapeutics Inc's Key Ratios
Applied Therapeutics Inc has a market cap of $47.58 million, indicating a price to book ratio of 4.2194 and a price to sales ratio of 0.
In the last 12-months Applied Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Applied Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Applied Therapeutics Inc’s operating margin was 0% while its return on assets stood at -64.98% with a return of equity of -197.73%.
In Q3, Applied Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Applied Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.99 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Applied Therapeutics Inc’s profitability.
Applied Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.0462. Its price to sales ratio in the trailing 12-months stood at 0.
Applied Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $56.68 million
- Total Liabilities
- $46.51 million
- Operating Cash Flow
- $5.02 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Applied Therapeutics Inc ended 2024 with $56.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $56.68 million while shareholder equity stood at $9.63 million.
Applied Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $46.51 million in other current liabilities, 5000.00 in common stock, $-334394000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $40.39 million and cash and short-term investments were $47.38 million. The company’s total short-term debt was $470,000 while long-term debt stood at $0.
Applied Therapeutics Inc’s total current assets stands at $55.51 million while long-term investments were $0 and short-term investments were $6.99 million. Its net receivables were $276000.00 compared to accounts payable of $6.97 million and inventory worth $0.
In 2024, Applied Therapeutics Inc's operating cash flow was $5.02 million while its capital expenditure stood at $0.
Comparatively, Applied Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.6
- 52-Week High
- $2.73
- 52-Week Low
- $0.5
- Analyst Target Price
- $15
Applied Therapeutics Inc stock is currently trading at $1.6 per share. It touched a 52-week high of $2.73 and a 52-week low of $2.73. Analysts tracking the stock have a 12-month average target price of $15.
Its 50-day moving average was $1.47 and 200-day moving average was $1.2 The short ratio stood at 2.55 indicating a short percent outstanding of 0%.
Around 1655.7% of the company’s stock are held by insiders while 6890.8% are held by institutions.
Frequently Asked Questions About Applied Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.